AtriCure Inc

Stage 2 advancing regime and active Lockout Rally pattern reinforce a bullish medium-term bias, while the Lockout Rally override supersedes overbought timing concerns and permits immediate participation in the current breakout above key EMAs and prior highs.

• ↑Q1 2026 revenue $141.2M (+14.3% YoY), U.S. up 14.9%.
• ↑Box NOAF trial 300/960 patients enrolled, ahead of timeline.
• ↓Profitability score deeply negative, indicating efficiency challenges.